Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 30;15(1):4713.
doi: 10.5826/dpc.1501a4713.

Significance of Clinical-Pathological Correlation in Ponatinib Reactions

Judith Monserrat Corona-Herrera  1 , Fanny Carolina Lopez-Jimenez  1 , Verónica Monserrat Díaz Sánchez  1 , Betzabé Quiles-Martínez  1 , Marcela Saeb-Lima  2 , Silvia Méndez-Flores  1
Affiliations

Significance of Clinical-Pathological Correlation in Ponatinib Reactions

Judith Monserrat Corona-Herrera et al. Dermatol Pract Concept. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None.

Figures

Figure 1
Figure 1
(A–C) Plaques with erythematous purpuric and ochre hues, arranged in a reticular pattern and surrounded by a halo of increased erythema. In some central areas of the lesions, there is evidence of fine adherent scaling. (D) Hypopigmented post-inflammatory patches with a reticulated appearance.
Figure 2
Figure 2
(A,B) Skin biopsy of the back show pauci-inflammatory subepidermal blistering dermatosis with multiple necrotic keratinocytes and lymphocytic and neutrophilic infiltration (H&E, x4). (C,D) Higher magnification (x40).
See this image and copyright information in PMC

References

    1. Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91(4):482–3. doi: 10.1159/000351918. - DOI - PubMed
    1. Massaro F, Molica M, Breccia M. Ponatinib: A Review of Efficacy and Safety. Curr Cancer Drug Targets. 2018;18(9):847–56. doi: 10.2174/1568009617666171002142659. - DOI - PubMed
    1. Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117(3):620–22. doi: 10.1046/j.1365-2141.2002.03499.x. - DOI - PubMed
    1. Chaigne B, Lagier L, Aubourg A, et al. Stevens-Johnson Syndrome induced by masitinib. Acta Derm Venereol. 2012;92(2):210–2. doi: 10.2340/00015555-1196. - DOI - PubMed
    1. Danish M, Patel V, Arava S, Ahuja R. Ponatinib-induced desquamation-Unifying eponymous terminology for a rare adverse event. J Eur Acad Dermatol Venereol. 2024;38(3):e247–e249. doi: 10.1111/jdv.19553. - DOI - PubMed

LinkOut - more resources